Testosterone After Menopause: Evidence Gaps and Questions

Considering testosterone after menopause can bring up questions about possible benefits, safety, and how well the available evidence applies to an individual. A public meeting is one place those questions may be discussed, but the announcement of a meeting is not itself a clinical recommendation or a summary of what the evidence proves.

The FDA event page lists a public meeting on testosterone use in menopausal women on September 17, 2026, and a public-comment deadline of October 19, 2026. The meeting date has passed; the page is the source for the event details. For a personal decision, discuss your concerns and options with a licensed clinician.

What the FDA meeting does—and does not—tell you

A public meeting can draw attention to an issue and provide a setting for discussion. Its existence does not establish that testosterone is appropriate for a particular person, that a particular benefit has been proven, or that any specific approach is safe for everyone. The meeting page should not be treated as a substitute for individualized evaluation or as a clinical guideline.

The word “testosterone” can also refer to different products and approaches. When discussing the topic, ask what product, purpose, and evidence a clinician is referring to. Do not assume that findings about one use or product automatically answer questions about another.

A useful distinction: “What has been studied?” and “What might be suitable for me?” are related questions, but they are not the same question. A clinician can help put the evidence and your circumstances into context.

Where to look for evidence gaps

Rather than assuming that all important questions have settled answers, ask what is known and what remains uncertain for the specific concern you want to address. Useful areas to clarify include:

• The goal of treatment: What symptom or concern is being considered, and what change would count as meaningful to you?
• Who the evidence applies to: Were the people studied similar to you in the ways that matter for this decision? What differences limit how confidently results can be applied?
• The size and duration of any benefit: What outcome was measured, how long was it followed, and how certain is the estimate?
• Safety information: What possible harms were examined, over what period, and what remains unknown?
• The specific product or approach: Does the evidence refer to the same formulation and use being discussed with you?
• Alternatives: What other approaches could be considered for your concern, and what are their trade-offs?

These are questions to investigate, not claims that a benefit or harm has been established. The FDA event page identifies the topic of a public discussion; it does not, by itself, answer these clinical questions. Review the FDA meeting information and ask a licensed clinician to explain how any evidence relates to your situation.

Questions to take to a clinician

You do not need to arrive with a preferred treatment in mind. A clear description of what you hope to address can help make the conversation more useful. Consider writing down your questions in advance:

1. What could be contributing to the concern I want to discuss? What information would you need to understand the context?
2. What evidence supports considering testosterone for this particular goal? How certain is that evidence, and where are the limits?
3. Does the evidence match the product and approach being proposed? If not, what is different?
4. What potential benefits and harms should I weigh? Which details are well understood, and which are uncertain?
5. What other options could fit my goals? How would we compare their possible benefits, burdens, and uncertainties?
6. How would we know whether a plan is helping or causing problems? What follow-up and reassessment would be appropriate?
7. What should I understand before making a decision? Ask for an explanation of any unfamiliar terms, records, or proposed next steps.

It is reasonable to ask for time to consider the information, request clarification, or seek another qualified opinion. A clinician should be able to explain the reasoning behind a recommendation and discuss uncertainty without promising an outcome.

A practical way to organize the discussion

Bring a concise list of concerns and any information you think may be relevant. You can also note what you have already tried or discussed, without assuming that any one detail determines the right choice. The aim is a shared conversation, not a predetermined answer.

If you are considering a consultation

Atlanta Medical Institute is located in Sandy Springs and serves adults in the metro Atlanta area. A consultation is an opportunity to discuss your concerns and whether an evaluation may be appropriate; availability of services depends on an evaluation. The clinic's online booking availability can change, so consult the current consultation information. The patient portal is separate from appointment booking and does not indicate that a booking time is available.

The initial consultation fee is $125. If you have questions about whether a consultation is relevant to your needs, contact the clinic before booking. A clinician can discuss options with you, but no particular treatment or result is assured.

A measured next step

Testosterone use after menopause is a topic for careful discussion, not a conclusion to draw from a meeting announcement alone. Focus on the concern you want to address, ask how strong and applicable the evidence is, and invite a licensed clinician to explain both the uncertainties and the alternatives. Use the conversation to make an informed decision that reflects your goals and circumstances.